To test the hypothesis that new-onset atrial fibrillation is related to clinical heart failure progression , in 2392 patients without atrial fibrillation at randomization in the Beta-blocker Evaluation of Survival Trial we measured clinical endpoints in patients who did ( Group 1 , n = 190 ) or did not ( Group 2 , n = 2202 ) develop new-onset atrial fibrillation .